Sangart develops investigational biopharmaceuticals designed to enhance perfusion and deliver gases to ischemic tissues. Its lead programs include MP4OX, intended to improve oxygen delivery in capillaries for severe traumatic hemorrhage, and MP4CO, intended to deliver therapeutic carbon monoxide for sickle cell crises. The company plans to use new funding to advance development of MP4OX in severe traumatic hemorrhage and MP4CO in sickle cell disease. Sangart operates from San Diego, CA and maintains a European office in London, UK. The company is led by President and CEO Brian O'Callaghan. Since its inception in 1998, Sangart has raised more than $230m in total funding.

Total raised

$50M

Funding rounds

1

Latest round

Series G

Latest activity

Apr 2011